Drugs / IL-12 pDNA Adjuvant
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03181789 | Oct 2017 → Oct 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01578889 | May 2012 → Sep 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-12 pDNA Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03181789 ↗ |
| Known as | pIL-12 | “The HIV Vaccine Trials Network (HVTN) 087 vaccine trial assessed the effect of increasing doses of pIL-12 (interleukin-12 delivered as plasmid DNA) adjuvant on the...” PMID 28931520 ↗ Nov 2017 |
| Modality | Other / unclassified | “interleukin-12 delivered as plasmid DNA” PMID 28931520 ↗ Nov 2017 |
| Route | Intramuscular | “given by intramuscular (IM) injection with electroporation (EP)” NCT03181789 ↗ |